AmpliPhi Biosciences (APHB) Short Interest Down 9.5% in March

AmpliPhi Biosciences (NYSEAMERICAN:APHB) was the target of a large decline in short interest in the month of March. As of March 29th, there was short interest totalling 1,103,899 shares, a decline of 9.5% from the March 15th total of 1,219,178 shares. Currently, 7.1% of the company’s shares are short sold. Based on an average trading volume of 535,566 shares, the short-interest ratio is currently 2.1 days.

In other AmpliPhi Biosciences news, Director Jeremy Curnock Cook acquired 46,666 shares of the company’s stock in a transaction that occurred on Thursday, November 22nd. The stock was purchased at an average price of $7.40 per share, for a total transaction of $345,328.40. Following the completion of the acquisition, the director now owns 330 shares of the company’s stock, valued at approximately $2,442. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

How to Become a New Pot Stock Millionaire

Shares of NYSEAMERICAN:APHB opened at $1.19 on Wednesday. AmpliPhi Biosciences has a twelve month low of $0.67 and a twelve month high of $5.00.

AmpliPhi Biosciences (NYSEAMERICAN:APHB) last issued its quarterly earnings data on Wednesday, March 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.11. AmpliPhi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.03 million.

Separately, HC Wainwright set a $6.00 price target on shares of AmpliPhi Biosciences and gave the stock a “buy” rating in a report on Thursday, March 15th.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at

AmpliPhi Biosciences Company Profile

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.

Receive News & Ratings for AmpliPhi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmpliPhi Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply